Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ribavirin elaidate

Drug Profile

Ribavirin elaidate

Alternative Names: CP-4033; Ribavirin-5'-elaidic acid ester ; UNII-4LU13X0I13

Latest Information Update: 17 Nov 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clavis Pharma
  • Developer Translational Therapeutics
  • Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Eukaryotic initiation factor 4E inhibitors; Oncogene protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer

Highest Development Phases

  • No development reported Thyroid cancer

Most Recent Events

  • 17 Nov 2013 No development reported - Preclinical for Thyroid cancer in USA (unspecified route)
  • 09 Oct 2013 Clavis Pharma is now called Aqualis
  • 02 Sep 2011 Ribavirin elaidate receives Orphan Drug status for Thyroid cancer in the USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top